## Xyrem (sodium oxybate) Xywav (calcium, magnesium, potassium, and sodium oxybates)

	719 11 011 (0 011 011 011 111, 111	, p		e de direiti d'ary le direct,
	Member	and Medicati	on Informatio	n (required)
Member ID:			Member Name:	
DOB:			Weight:	
Medication Name/ Strength:			Dose:	
Directi	ons for use:			
Provider Information (required)				
Name		NPI:		Specialty:
Contact Person: Office P		Office Phone:		Office Fax:
FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992				
Criteria	a for Approval: (all criteria must b	ne met) <b>Max Dose 9</b> a	ım per dav	
□ Patient is 7 years or older.				
	☐ Diagnosis of ☐ Cataplexy associated with narcolepsy <b>OR</b> ☐ Excessive daytime sleepiness with narcolepsy			
	☐ Patient is enrolled in Xywav and Xyrem REMS Program.			
	☐ Prescribed by or in consultation with a physician that is board certified in sleep medicine.			
	Prescriber is enrolled in Xywav and Xyrem REMS Program and attests to complying with safety requirements.			
	Ruled out concomitant use of sedative-hypnotics, alcohol, or CNS depressants. Chart Note Page #:			
	Insufficient response to adequately dosed and appropriate length of treatment with modafinil and/or armodafinil. (concomitant use is allowed)			
				Chart Note Page #:
Dates of therapy: Details of Failure:				
Additio	onal Criteria for Xywav:			
Clinically significant requirement for sodium restriction. (Describe and include re				clude relevant chart notes)
	Description:			Chart Note Page #:
	horization Criteria: ed letter of medical necessity or u	pdated chart notes o	demonstrating positi	ive clinical response.
Initial A	Authorization: Up to three (3) mo	onths		
Re-aut	horization: Up to one (1) year			
PROVII	DER CERTIFICATION			
I hereb	y certify this treatment is indicate	ed, necessary and mo	eets the guidelines fo	or use.
 Prescri	ber's Signature			 Date